3 Cash-cow Staples Set to Crater 40% Once Ozempic Scales
Every Sunday, I share exactly what I’m buying: real-time updates for Zero Bound members. No fluff, just a clear look at how I’m building my portfolio toe live off dividends.
I focus on a mix of high-yield and dividend growth stocks to create a steady, growing stream of passive income
I hit $60,000/month in dividends just recently. And honestly-anyone can follow the same path. You just need the right plan and consistency.
This is for the small percentage of investors who understand that hesitation isn't just a strategic failure; it's a choice to remain the punchline. I already told you how I milked one catalyst for a 437% Moonshot yesterday.
The doors will be sealed shut when the timer below hits zero.
This is your one opportunity to stop playing their rigged game and start using the system that was built to beat it. The choice is yours. Buy here.
The System: Founding Member Access Now Open
I am opening 100 "Founding Member" spots.
This is a one-time offer.
For a single payment of $250, you will receive lifetime access to everything. Every Signal Brief, every Catalyst Alert, every piece of analysis. You will pay once and never pay again.
This is not a typical subscription. It is a stake in this operation. I am seeking a small circle of operators who understand the value of what is being built here.
We launched recently. As of this morning, I have 6 spots left.
When the remaining 66 spots are gone, they are gone. The price for access will then become a recurring annual subscription at a significantly higher price point.
This is the only time lifetime access will ever be offered.
The choice is yours.
Click Here to Claim Your Founding Member Spot Before They Are Gone.
A single company, Novo Nordisk, is now so large it is warping the GDP of its home country, Denmark.
The financial media has, correctly, declared this a revolution.
Every fund ma nager on the planet is fighting for a piece of the pharma giants that created this miracle.
They are celebrating a victory. And in doing so, they are completely missing the war.
The real question is not "who wins?" The question is, "who are the uncounted dead?"
The Roar of the Crowd
The narrative is a masterpiece of simplicity and virtue.
A drug that eradicates obesity, a plague of the modern world.
Buying the stock is a vote for progress, for a healthier future.
The herd loves this trade.
It feels good.
It seems obvious.
It is, therefore, a perfect trap, blinding them to the second-order effects.
They are focused on the cure, forgetting that every cure creates a new class of casualty.
The Chemical Imperative
It’s not about the clinical trial.
It is in the checkout data from Walmart, where management now openly admits they can track a "pullback in food consumption" from GLP-1 users.
This is not a "diet."
This is a chemical intervention in the brain's reward system.
We are not just talking about lower calorie counts.
These drugs systematically dismantle "food noise"—the biological craving for the hyper-palatable, high-margin products that form the bedrock of the consumer staples sector.
The effect is so profound it extends beyond food, demonstrably reducing cravings for other addictive substances like alcohol.
This is a chemical assault on the entire trillion-dollar economy of human craving.
The Mispricing of Obsolescence
The market has priced the pharma companies for a utopian future.
It has utterly failed to price a long list of other companies for extinction.
While the herd chases pharma, we are auditing the victims.
The market is still pricing dialysis providers like DaVita and sleep apnea device makers like ResMed as if their customers' chronic conditions are permanent.
They are not.
They are a direct consequence of the obesity epidemic that is now being chemically reversed.
The business models of these companies are built on a disease that is being cured, yet their stock prices reflect a state of ignorant bliss.
The Collateral Damage Report
The market is a narrative machine, but it is ultimately governed by biology.
The narrative is about curing a disease.
The biology is that the cure works by making the products and services of adjacent industries obsolete.
A massive, structural mispricing has occurred.
The market has celebrated the architects of the cure but has failed to mark down the value of the businesses that thrived on the sickness.
They are betting on the doctors.
We are calculating the collateral damage.
The Window Is Closing
This is not a secret anymore.
The whispers are already appearing in institutional research notes, with analysts at Morgan Stanley now projecting permanent, structural revenue destruction for entire sectors.
The herd will eventually notice the real story is not about the winners, but about the slow, painful collapse of the losers.
By then, the trade will be gone.
Our active investigation is focused on the three companies whose balance sheets are most acutely vulnerable to this chemical obsolescence.
Their next earnings call will not be an update; it will be a confession.
Paid members get the full brief.